Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.39 |
| ▸ | ADH1B | P00325 | 1/20 | 0.37 |
| ▸ | ADH1C | P00326 | 1/20 | 0.37 |
| ▸ | ADH1A | P07327 | 1/20 | 0.37 |
| ▸ | ADH4 | P08319 | 1/20 | 0.37 |
| ▸ | ADH7 | P40394 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 5/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | PRKCA | P17252 | 7/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30797314 | 0.81 | GAA (0.42) | ZDHHC7ADH1BADH1CADH1AADH4 | |
| SCHEMBL27505908 | 0.77 | BIRC2 (0.48) | ZDHHC7ADH1BADH1CADH1AADH4 | |
| SCHEMBL9719704 | 0.72 | FAAH (0.50) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL6670003 | 0.72 | FAAH (0.50) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL8689945 | 0.72 | CA1 (0.44) | ZDHHC7ADH1BADH1CADH1AADH4 | |
| SCHEMBL4532260 | 0.72 | FAAH (0.50) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL11371381 | 0.72 | FAAH (0.50) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL9719708 | 0.72 | FAAH (0.50) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL5595510 | 0.70 | FAAH (0.47) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL5595513 | 0.70 | FAAH (0.47) | ADH1BADH1CADH1AADH4ADH7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10450335-B2 | Antiviral oxime phosphoramide compounds | MERCK SHARP & DOHME CORP. (US) | 2019-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10450335-B2 | Antiviral oxime phosphoramide compounds | TYMP, MTAP, POLR2E | ZDHHC7 2650/4885ADH1B 713/4885ADH1C 2691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.